-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga·02/05/2026 12:05:40
Listen to the news

Gainers

  • CytoMed Therapeutics (NASDAQ:GDTC) shares increased by 27.1% to $1.08 during Thursday's pre-market session. The market value of their outstanding shares is at $9.9 million.
  • Anbio Biotechnology (NASDAQ:NNNN) stock increased by 18.15% to $27.21. The market value of their outstanding shares is at $1.0 billion.
  • ALX Oncology Holdings (NASDAQ:ALXO) shares moved upwards by 16.41% to $2.34. The company's market cap stands at $263.7 million.
  • Nexalin Technology (NASDAQ:NXL) stock moved upwards by 16.19% to $0.66. The market value of their outstanding shares is at $10.5 million.
  • Can Fite Biopharma (AMEX:CANF) shares moved upwards by 15.34% to $4.66. The company's market cap stands at $5.2 million.
  • Align Technology (NASDAQ:ALGN) shares moved upwards by 10.43% to $178.13. The company's market cap stands at $11.6 billion. As per the press release, Q4 earnings came out yesterday.

Losers

  • ENDRA Life Sciences (NASDAQ:NDRA) shares decreased by 11.8% to $3.43 during Thursday's pre-market session. The market value of their outstanding shares is at $4.5 million.
  • Omnicell (NASDAQ:OMCL) shares decreased by 11.12% to $41.5. The company's market cap stands at $2.1 billion. As per the press release, Q4 earnings came out today.
  • Agape ATP (NASDAQ:ATPC) shares declined by 9.05% to $0.08. The market value of their outstanding shares is at $4.2 million.
  • TuHURA Biosciences (NASDAQ:HURA) shares fell 8.93% to $0.42. The market value of their outstanding shares is at $26.1 million.
  • Accuray (NASDAQ:ARAY) shares fell 7.82% to $0.7. The market value of their outstanding shares is at $85.7 million. As per the press release, Q2 earnings came out yesterday.
  • Tempest Therapeutics (NASDAQ:TPST) shares decreased by 7.57% to $2.2. The company's market cap stands at $11.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.